The effect of Cynara Scolymus on hyperlipidemia

To determine the effectiveness of Cynara Scolymus extract on lipid profile of hemodialysis patients compared with placebo

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017102022689N5

Enrollment

Registered

2017-11-05

Start date

2017-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease. End stage kidney disease: in allograft failure NOS on dialysis or without dialysis or transplant , Renal retinitis , Uraemic: apoplexia+ , dementia+ , neuropathy+ , paralysis+ , pericarditis

Interventions

Intervention 1: In the intervention group, the samples receive artichoke capsules ( 320 mg) up to 6 weeks twice daily ( 8 am and 8 pm ). All samples in both intervention and control groups, routinely

Treatment - Drugs

In the intervention group, the samples receive artichoke capsules ( 320 mg) up to 6 weeks twice daily ( 8 am and 8 pm ). All samples in both intervention and control groups, routinely receive atorvast

In the placebo group, the samples receive placebo capsule containing starch ( 320 mg) up to 6 weeks twice daily ( 8 am and 8 pm ). All samples in both intervention and control groups, routinely receiv

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Entry criteria:History of hyperlipidemia in hemodialysis patient; with failure to control blood lipids (serum LDL =100 mg/dl );with Age over 18 and under 70 years old;with dialysis 2-3 time weekly every times for 3-4 hours;with The patient's willingness to participate in the research;having a case in considered nephrology center without exclusion criteria;BMI less than 18;Artichoke use at least one month before the start of the study; unwillingness to continue to cooperate or traveling or death; pregnancy and lactation; the development of side effects of drug; lack of medication over a week.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum LDL concentration. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.	—

Secondary

Measure	Time frame
Serum triglyceride concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum HDL concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum cholestrol concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum CRP concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum ESR concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum ferritin concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum iron concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum TIBC concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.	—

Measure

Time frame

Serum triglyceride concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum HDL concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum cholestrol concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum CRP concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum ESR concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum ferritin concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum iron concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum TIBC concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEbrahim Khadem

School of traditional medicine Tehran university of medical sciences ,Vice chancellor for student in

Dr.Ebrahimkhadem@yahoo.com+98 21 8897 4638

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026